Avanos Medical (NYSE:AVNS) Issues FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.850-0.950 for the period, compared to the consensus EPS estimate of 0.850. The company issued revenue guidance of $690.0 million-$700.0 million, compared to the consensus revenue estimate of $679.6 million.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AVNS. Wall Street Zen cut shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avanos Medical in a research note on Tuesday, October 14th. Finally, Zacks Research raised shares of Avanos Medical to a “hold” rating in a research note on Tuesday, August 12th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce”.

Avanos Medical Trading Down 3.2%

NYSE AVNS traded down $0.36 during trading hours on Wednesday, reaching $10.94. The company had a trading volume of 574,539 shares, compared to its average volume of 540,565. The stock has a 50-day moving average of $11.74 and a 200 day moving average of $11.93. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $21.12. The company has a current ratio of 2.64, a quick ratio of 1.58 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $507.52 million, a P/E ratio of -1.08 and a beta of 1.19.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. The company had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. During the same quarter in the prior year, the company posted $0.33 earnings per share. Avanos Medical’s revenue for the quarter was up 4.3% compared to the same quarter last year. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. As a group, research analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Insider Activity

In other Avanos Medical news, Director Gary Blackford purchased 40,000 shares of Avanos Medical stock in a transaction dated Wednesday, August 13th. The shares were acquired at an average price of $10.99 per share, with a total value of $439,600.00. Following the completion of the transaction, the director owned 40,000 shares of the company’s stock, valued at $439,600. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.64% of the company’s stock.

Institutional Trading of Avanos Medical

Several hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC purchased a new stake in shares of Avanos Medical during the second quarter worth approximately $1,145,000. Engineers Gate Manager LP increased its stake in shares of Avanos Medical by 180.2% during the second quarter. Engineers Gate Manager LP now owns 86,597 shares of the company’s stock worth $1,060,000 after buying an additional 55,687 shares during the period. CANADA LIFE ASSURANCE Co increased its stake in Avanos Medical by 10.6% in the second quarter. CANADA LIFE ASSURANCE Co now owns 79,871 shares of the company’s stock valued at $977,000 after purchasing an additional 7,647 shares during the last quarter. Jump Financial LLC purchased a new position in Avanos Medical in the second quarter valued at approximately $696,000. Finally, Jane Street Group LLC increased its stake in Avanos Medical by 5.8% in the second quarter. Jane Street Group LLC now owns 56,044 shares of the company’s stock valued at $686,000 after purchasing an additional 3,062 shares during the last quarter. Institutional investors and hedge funds own 95.17% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.